Engineered immune cells clear deadly childhood brain tumors in mice
โฎ BeforeChildren with diffuse midline glioma have an almost always fatal prognosis within a year.
โ
NowIn two mouse models, the new engineered cells completely eliminated the tumours; human trials have not yet been reported.
In short
- UC San Francisco scientists built B-SYNC CAR-T cells that stay inactive until they reach the brain.
- In two mouse models, the cells completely eliminated diffuse midline glioma, a childhood brain cancer.
- The cancer is almost always fatal within a year; the work is still in mice, not people.
Why it's good news
Diffuse midline glioma is aggressive and almost always fatal within a year, and few treatments reach it. This therapy is designed to stay inactive until it reaches the brain, which may limit effects elsewhere in the body. The results so far come from mice, so the next step is testing for safety and effect in people.
Advertisement
From ScienceDaily
Scientists at UC San Francisco have developed a powerful new cancer therapy that remains inactive until it reaches the brain, where it switches on to attack deadly tumors. The engineered immune cells, called B-SYNC CAR-T cells, completely eliminated diffuse midline glioma (DMG), an aggressive childhood brain cancer that is almost always fatal within a year, in two mouse models.
Ask this story
More like this
Advertisement